For a long time, the cure for diabetes type 1 and type 2 has relied on agonizing insulin shots for patients or insulin infusion via mechanical pumps. Regarding this, experts have been creating artificial pancreatic beta cells with the he…
DelveInsight's, "Sensorineural Hearing Loss- Pipeline Insight, 2022," report provides comprehensive insights about 15+ companies and 15+ pipeline drugs in Sensorineural Hearing Loss pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
Sensorineural Hearing Loss Understanding
Sensorineural Hearing Loss: Overview
Hearing loss is a common complaint for which referrals are frequently made to secondary care for an otolaryngologist's attention. There are two types of hearing loss; conductive and sensorineural hearing loss. Sensorineural hearing loss (SNHL) is the most common type and accounts for the majority of all hearing loss. SNHL refers to any cause of hearing loss due to a pathology of the cochlea, auditory nerve, or central nervous system. The incidence of sensorineural hearing loss varies in different countries. In the United States, sudden SNHL affects between 5-27 per 100,000 people each year, with approximately 66,000 new annual cases. Due to different studies using varying thresholds when classifying hearing loss, there is little consensus in the literature regarding the epidemiology of age-related hearing known as presbycusis. In presbycusis, hearing loss prevalence doubles every decade of life from the second through to the seventh decade, and is nearly universal past the eighth decade of life. Sensorineural hearing loss results from damage to the hair cells within the inner ear, the vestibulocochlear nerve, or the brain's central processing centers. This differs from a conductive hearing loss, which results from the inability of sound waves to reach the inner ear. Sensorineural hearing loss is managed according to the underlying cause. In acute cases where no cause is found and suspected to be of idiopathic origin, a routine brain MRI with detail to the internal auditory meatus should be requested. Sensorineural hearing loss tends to have a typical slow progression and can be managed with conservative measures and hearing aids for the vast majority of patients with regular follow-up appointments and audiograms. If patients are eligible, even profound hearing loss can be rehabilitated with a cochlear implant. Many patients with SNHL suffer from other associated symptoms such as tinnitus and dizziness, which they often find more challenging to tolerate than hearing loss. Sensorineural hearing loss can significantly impact a patient's quality of life and ability to carry out daily living activities. It is essential not only for patients to be educated on how to live with the condition but also for their family members to gain insight into the patients' challenges. Sensorineural hearing loss will affect a large part of the population at some point in their lifetime.
"Sensorineural Hearing Loss- Pipeline Insight, 2022" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Sensorineural Hearing Loss pipeline landscape is provided which includes the disease overview and Sensorineural Hearing Loss treatment guidelines. The assessment part of the report embraces, in depth Sensorineural Hearing Loss commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Sensorineural Hearing Loss collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Sensorineural Hearing Loss R&D. The therapies under development are focused on novel approaches to treat/improve Sensorineural Hearing Loss.
Sensorineural Hearing Loss Emerging Drugs Chapters
This segment of the Sensorineural Hearing Loss report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Sensorineural Hearing Loss Emerging Drugs
- PIPE 505 : Pipeline Therapeutics
PIPE-505, is Pipeline Therapeutics proprietary, locally delivered, gamma secretase inhibitor that targets two key regenerative pathways in the cochlea, the Netrin/DCC pathway for synaptic regeneration and the Notch pathway for outer hair cell regeneration. These pathways are linked to the two main areas of deficient auditory function in Sensorineural Hearing loss, intelligibility, and audibility, respectively.
- LY 3056480 : Audion Therapeutics
Audion's lead candidate (LY 3056480) has undergone a thorough and extensive preclinical characterization in multiple model systems prior to initiation of the clinical studies. These studies include effects of the drug on damaged inner ear tissue, inner ear PK studies to determine drug exposure using different formulations and formal ototoxicity studies to exclude toxic effects on normal hair cells and inner ear tissues. The lead candidate (LY 3056480) has now completed clinical Phase 1 and Phase 2 testing, and delivered encouraging results that supported the advancement into Phase 2b studies.
- OTO 413 : Otonomy
OTO-413 is a sustained-exposure formulation of brain-derived neurotrophic factor (BDNF) in development for the treatment of hearing loss. In December 2020, Otonomy, announced positive top-line results from a Phase 1/2 clinical trial of OTO-413, demonstrating that a single intratympanic injection of OTO-413 was well-tolerated and showed therapeutic activity across multiple speech-in-noise hearing tests. Otonomy is currently conducting a Phase 2a clinical trial for OTO-413, with top-line results expected early in the second quarter of 2022, and are also evaluating the safety of higher dosing.
Further product details are provided in the report ..
Sensorineural Hearing Loss: Therapeutic Assessment
This segment of the report provides insights about the different Sensorineural Hearing Loss drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Sensorineural Hearing Loss
There are approx. 15+ key companies which are developing the therapies for Sensorineural Hearing Loss. The companies which have their Sensorineural Hearing Loss drug candidates in the most advanced stage, i.e. phase II include, Audion Therapeutics.
- Phases
DelveInsight's report covers around 15+ products under different phases of clinical development like
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
Sensorineural Hearing Loss pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
- Intra-articular
- Intraocular
- Intrathecal
- Intravenous
- Ophthalmic
- Oral
- Parenteral
- Subcutaneous
- Topical
- Transdermal
- Molecule Type
Products have been categorized under various Molecule types such as
- Oligonucleotide
- Peptide
- Small molecule
- Product Type
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
Sensorineural Hearing Loss: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Sensorineural Hearing Loss therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Sensorineural Hearing Loss drugs.
Sensorineural Hearing Loss Report Insights
- Sensorineural Hearing Loss Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
Sensorineural Hearing Loss Report Assessment
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Key Questions
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Sensorineural Hearing Loss drugs?
- How many Sensorineural Hearing Loss drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Sensorineural Hearing Loss?
- What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Sensorineural Hearing Loss therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Sensorineural Hearing Loss and their status?
- What are the key designations that have been granted to the emerging drugs?
Key Players
- Pipeline Therapeutics
- Audion Therapeutics
- Otonomy
- Sound Pharmaceuticals
- Decibel Therapeutics
- Frequency Therapeutics
- Acousia Therapeutics
- Sensorion
- Altamira Therapeutics
- Sound Pharmaceuticals
Key Products
- DB-OTO
- FX 322
- Otopotin
- Arazasetron
- PIPE-505
- LY 3056480
- OTO 413
- DB 104
- Brimapitide
- Ebselen